{
  "id": 18620579,
  "title": "Ligand Pharmaceuticals director sells $90,237 in common stock",
  "url": "https://urgent.news/2026/11/07/ligand-pharmaceuticals-director-sells-90-237-in-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T02:16:14.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ligand-pharmaceuticals-director-sells-90237-in-common-stock-93CH-5009554"
  },
  "original_language": "en",
  "account": null,
  "summary": "Investing.com reports that Jason Aryeh, a director at Ligand Pharmaceuticals Inc (LGND), sold 282 shares of the company's common stock for a total of $90,237 on November 4, 2026. The sale comes as the stock price trades near its 52-week high of $326.63, following a 46% increase over the past six months. Aryeh, who is also the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP, now directly holds 108,476 shares of LGND common stock, with an additional 8,000 shares indirectly held by JALAA Equities, LP and JLV Investments, LP and their affiliates. Despite the sale, LGND's recent strong third-quarter earnings, which surpassed Wall Street's expectations, and its strategic adjustments have been noted.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}